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Significant progress has been made, but the morbidity and mortality from this syndrome continues to be unacceptably high. Thus, it would be an exciting from Diasorin. Dr. Gupta has reported that he has no relationships relevant to the contents of this paper to disclose.
The study by Witte et al. (13) The primary endpoint analysis was negative. The authors, however, noted higher variability in the 6-minute walk test measurements than originally expected. Thus, the study was underpowered to detect clinically relevant differences in this endpoint.
The high rate of attrition was also a limitation. Only Trial: Cardiac Resynchronization Therapy) (18) . In that trial, each 5% increase in LVEF from baseline was associated with a 28% to 50% reduction in the risk of heart failure hospitalization or death (18) .
On the other hand, it is clear that the secondary endpoint findings in the VINDICATE study can be regarded as no more than hypothesis generating. thomas.j.wang@vanderbilt.edu.
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